Compounds > 2-(1,3-benzoxazol-2-ylthio)-N-(4-phenyl-2-thiazolyl)acetamide
Page last updated: 2024-09-28

2-(1,3-benzoxazol-2-ylthio)-N-(4-phenyl-2-thiazolyl)acetamide

Cross-References

ID SourceID
PubMed CID2059463
CHEMBL ID1459473
CHEBI ID121850

Synonyms (20)

Synonym
EU-0051503
smr000264030
MLS000409043
OPREA1_066407
OPREA1_788667
2-(1,3-benzoxazol-2-ylsulfanyl)-n-(4-phenyl-1,3-thiazol-2-yl)acetamide
STK003063
CHEBI:121850
ZINC02500760
AKOS001073205
HMS2562E10
CCG-25887
AB00542996-07
CHEMBL1459473
2-(1,3-benzoxazol-2-ylthio)-n-(4-phenyl-2-thiazolyl)acetamide
Q27210445
sr-01000515493
SR-01000515493-1
NCGC00302452-01
Z19650936

Drug Classes (1)

ClassDescription
benzoxazoleCompounds based on a fused 1,2- or 1,3-oxazole and benzene bicyclic ring skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (12)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CruzipainTrypanosoma cruziPotency31.62280.002014.677939.8107AID1476
LuciferasePhotinus pyralis (common eastern firefly)Potency21.33130.007215.758889.3584AID588342
glp-1 receptor, partialHomo sapiens (human)Potency31.62280.01846.806014.1254AID624417
ClpPBacillus subtilisPotency39.81071.995322.673039.8107AID651965
ATAD5 protein, partialHomo sapiens (human)Potency13.77820.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency16.36010.000811.382244.6684AID686978
Microtubule-associated protein tauHomo sapiens (human)Potency14.31520.180013.557439.8107AID1460; AID1468
P53Homo sapiens (human)Potency8.91250.07319.685831.6228AID504706
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency14.58100.00419.984825.9290AID504444
mitogen-activated protein kinase 1Homo sapiens (human)Potency35.48130.039816.784239.8107AID1454
survival motor neuron protein isoform dHomo sapiens (human)Potency10.00000.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceDescriptionRelationhip StrengthStudiesTrialsClassesRoles
6-hydroxychlorzoxazone[no description available]low00benzoxazole
benzoxazolone[no description available]low00benzoxazoleallelochemical;
phytoalexin
zoxazolamine[no description available]low00benzoxazole
6-methoxybenzoxazolinone[no description available]low00aromatic ether;
benzoxazole		antibacterial agent;
anticonvulsant;
antifungal agent;
muscle relaxant;
plant metabolite
cincreasin[no description available]low00benzoxazole;
organobromine compound
3-methyl-1,3-benzoxazole-2-thione[no description available]low00benzoxazole
2-[(4-nitrophenyl)methylthio]-1,3-benzoxazole[no description available]low00benzoxazole
2-[(2-nitrophenyl)methylthio]-1,3-benzoxazole[no description available]low00benzoxazole
2-(1,3-benzoxazol-2-ylthio)propanoic acid[no description available]low00benzoxazole
3-(2-oxo-1,3-benzoxazol-3-yl)-N-phenylpropanamide[no description available]low00benzoxazole
2-(4-chlorophenoxy)-N-(2-pyridin-4-yl-1,3-benzoxazol-5-yl)acetamide[no description available]low00benzoxazole
N-(2-pyridin-4-yl-1,3-benzoxazol-5-yl)butanamide[no description available]low00benzoxazole
N-[2-(3-pyridinyl)-1,3-benzoxazol-5-yl]butanamide[no description available]low00benzoxazole
N-[3-(2-phenylethyl)-2,4-dihydro-1H-1,3,5-triazin-6-yl]-1,3-benzoxazol-2-amine[no description available]low00benzoxazole
2-mercaptobenzoxazole[no description available]low00benzoxazole
2-(2-phenylethyl)-1,3-benzoxazol-5-amine[no description available]low00benzoxazole
3-(4-methylphenyl)sulfonyl-1,3-benzoxazol-2-one[no description available]low00benzoxazole
5-methyl-N-(4,5,6-trimethyl-2-pyrimidinyl)-1,3-benzoxazol-2-amine[no description available]low00benzoxazole
6-(1,3-benzoxazol-2-yl)-1,3-benzothiazol-2-amine[no description available]low00benzoxazole
4-oxo-3-pyrimido[2,1-b][1,3]benzoxazolecarboxylic acid ethyl ester[no description available]low00benzoxazole
N'-(1,3-benzoxazol-2-yl)benzohydrazide[no description available]low00benzoxazole
4-[(2-oxo-3H-1,3-benzoxazol-6-yl)sulfonylamino]benzoic acid methyl ester[no description available]low00benzoxazole
4-[(3-methyl-2-oxo-1,3-benzoxazol-6-yl)sulfonylamino]benzoic acid ethyl ester[no description available]low00benzoxazole
N-[2-(5-bromo-3-pyridinyl)-1,3-benzoxazol-5-yl]butanamide[no description available]low00benzoxazole
5-bromo-N-[2-(3-pyridinyl)-1,3-benzoxazol-5-yl]-2-furancarboxamide[no description available]low00benzoxazole
6-(2-chloro-1-oxoethyl)-3H-1,3-benzoxazol-2-one[no description available]low00benzoxazole
3-[(2-propoxyphenyl)methyl]-1,3-benzoxazol-2-one[no description available]low00benzoxazole
2-(1,3-benzoxazol-2-ylthio)-N-(6-bromo-1,3-benzothiazol-2-yl)acetamide[no description available]low00benzoxazole
N,N-diethyl-2-[(4-fluorophenyl)methylthio]-1,3-benzoxazole-5-sulfonamide[no description available]low00benzoxazole
2-(1,3-benzoxazol-2-ylthio)-1-(2,5-dimethyl-1-prop-2-enyl-3-pyrrolyl)ethanone[no description available]low00benzoxazole
5-methyl-3-(2-morpholino-2-oxoethyl)-1,3-benzoxazol-2(3H)-one[no description available]low00benzoxazole
3-(1,3-benzoxazol-2-ylthio)-5,5-dimethylcyclohex-2-en-1-one[no description available]low00benzoxazole
2-(1,3-Benzoxazol-2-ylsulfanyl)acetonitrile[no description available]low00benzoxazole
3-[2-(2-ethyl-1-piperidinyl)-2-oxoethyl]-1,3-benzoxazol-2-one[no description available]low00benzoxazole
2-chloro-N-(3-ethyl-2-oxo-1,3-benzoxazol-6-yl)acetamide[no description available]low00benzoxazole
2-[(3-bromo-5,7-dimethyl-2-imidazo[1,2-a]pyrimidinyl)methylthio]-1,3-benzoxazole[no description available]low00benzoxazole
1-(1,3-benzoxazol-2-yl)-N-[(4-ethylphenyl)methyl]-3-piperidinecarboxamide[no description available]low00benzoxazole
2-(1,3-benzoxazol-2-ylthio)-1-[3-(4-methylphenyl)-5-thiophen-2-yl-3,4-dihydropyrazol-2-yl]ethanone[no description available]low00benzoxazole
2-[2-oxo-6-(1-pyrrolidinylsulfonyl)-1,3-benzoxazol-3-yl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)acetamide[no description available]low00benzoxazole
N-(3-fluoro-4-methylphenyl)-3-methyl-2-oxo-1,3-benzoxazole-6-sulfonamide[no description available]low00benzoxazole
2-[2-oxo-6-(1-pyrrolidinylsulfonyl)-1,3-benzoxazol-3-yl]-N-(1-phenylethyl)acetamide[no description available]low00benzoxazole
3-[2-(2,3-dihydroindol-1-yl)-2-oxoethyl]-6-(1-piperidinylsulfonyl)-1,3-benzoxazol-2-one[no description available]low00benzoxazole
calcimycin[no description available]low00benzoxazole
4-[oxo-[2-(3-phenylpropyl)-1,3-benzoxazol-5-yl]methyl]-1-piperazinecarboxylic acid ethyl ester[no description available]low00benzoxazole
5-(4-amino-1-propan-2-yl-3-pyrazolo[3,4-d]pyrimidinyl)-1,3-benzoxazol-2-amine[no description available]low00benzoxazole
ConditionIndicatedRelationship StrengthStudiesTrials
Inflammation0low10
Innate Inflammatory Response0low10